secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0000950170-24-044593
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028
--------------------------------------------------------------------------------

- $280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.
- Strategic pivot to autoimmune diseases; first indication systemic lupus erythematosus (SLE); IND planned Q3 2024.
- CLN-978 Phase 1 B-NHL data: 1 complete response, rapid B cell depletion, low-grade CRS, no ICANS.
- Name change to Cullinan Therapeutics (Nasdaq: CGEM); reflects expanded focus beyond oncology.
- Enrollment in B-NHL study discontinued to focus on autoimmune development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/cgem-20240415.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer